美股A股
StockGist
Back
8-K2026-03-23· x-ai/grok-4.1-fast

MIRA · MIRA Pharmaceuticals, Inc.

0001493152-26-012085

SEC filing

Summary

MIRA Pharmaceuticals reported preclinical data showing Mira-55 produced no THC- or rimonabant-associated CNS side effects, including no psychogenic effects, sedation, catalepsy, motor impairment, or anxiogenic effects at oral doses of 10, 30, and 100 mg/kg. These results build on prior morphine-comparable pain relief in inflammatory pain models without opioid risks, supporting planned IND submission for inflammatory pain.

Key takeaways